CSIMarket Company Name, Ticker, Industry, else..
 
Blue Water Vaccines Inc  (NASDAQ: BWV)
Other Ticker:  
 
 
Price: $0.1802 $-0.01 -5.158%
Day's High: $0.2 Week Perf: -24.35 %
Day's Low: $ 0.18 30 Day Perf: -43.86 %
Volume (M): 534 52 Wk High: $ 0.00
Volume (M$): $ 96 52 Wk Avg: $0.00
Open: $0.20 52 Wk Low: $0.00



 Market Capitalization (Millions $) 0
 Shares Outstanding (Millions) 1
 Employees 11
 Revenues (TTM) (Millions $) 2
 Net Income (TTM) (Millions $) -35
 Cash Flow (TTM) (Millions $) -6
 Capital Exp. (TTM) (Millions $) 0

Blue Water Vaccines Inc
Blue Water Biotech Inc is a biotechnology company that focuses on developing innovative solutions for the water industry. They aim to address the global water crisis by creating sustainable and environmentally friendly technologies. The company's products and services include water treatment systems, wastewater management solutions, and water quality monitoring tools. Blue Water Biotech Inc combines cutting-edge scientific research with practical application to provide effective and efficient water treatment solutions. They strive to improve water quality and conserve resources for a better future.


   Company Address: 201 E. Fifth Street Cincinnati 45202 OH
   Company Phone Number: 620-4101   Stock Exchange / Ticker: NASDAQ BWV


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ANVS      % 
CLYM      % 
CNSP      % 
CYTK      % 
EVFM      % 
ZYME      % 
• View Complete Report
   



Stock Market Announcement

Onconetix's Breakthrough Treatment: A Paradigm Shift in Cancer Care

Published Tue, Dec 19 2023 12:00 PM UTC

Cancer Breakthrough: Onconetix s Innovative Treatment Shows Promising Results, Says CEO Dr. Neil Campbell
CINCINNATI, Dec. 19, 2023 - Onconetix, Inc., a leading biotechnology firm specializing in cancer research and treatment, recently released a breakthrough announcement outlining the remarkable progress they have made in their battle against the deadly disease. In a sh...
Merger and Acquisition

Blue Water Biotech Acquires Proteomedix: Revolutionizing Oncology with Advanced Prostate Cancer Diagnostics; Introducing Onconetix, the Future of Precise Cancer Care

Published Mon, Dec 18 2023 12:00 PM UTC

Transaction strengthens commercial business with addition of diagnostics product and initial focus on prostate cancer
Blue Water Biotech, a leading biotechnology company, has recently announced its acquisition of Proteomedix, a cutting-edge diagnostics company specializing in the development of advanced tests for urological diseases, particularly prostate cancer. This st...
Blue Water Biotech Inc

Major Pharmaceutical Preparations Company Faces Operating Challenges, Contracts in Financial Performance During Third Quarter of 2023

Blue Water Biotech Inc: A Company with Great Potential Despite Recent Setbacks
The Major Pharmaceutical Preparations industry has always been dominated by big players who have a long-standing history of success. However, in recent times, some lesser-known corporations have been making waves with their potential to disrupt the market. One such company is Blue Water Biotech Inc (BWV), which, despite facing some challenges, has shown promise and is poised to make a significant impact in the industry.
The recent financial results of BWV have raised eyebrows, with the company reporting an operating deficit of $-4.488083 million in the third quarter of 2023. While this may seem concerning on the surface, stakeholders of BWV are optimistic about the company's future prospects. They anticipate that a new business model, set to be implemented soon, will bring about positive changes and help turn the company's fortunes around.
Blue Water Biotech Inc

Blue Water Biotech Inc Takes Bold Steps to Weather Business Expenses Surge in Q2 2023



As the fiscal earnings cycle progresses, corporations across various industries have unveiled their results for the second quarter of 2023. Major players in the Pharmaceutical Preparations industry, including Blue Water Biotech Inc (BWV), have disclosed their operating losses. Although these figures may seem discouraging, a closer examination reveals a company determined to navigate challenges and establish a solid foundation for future success.
Comparing Q2 2023 Results:
BWV reported an operating loss of $-6.6496 million for the second quarter of 2023, compared to a loss of $-4.294885 million during the same period in 2022. This increase in losses can be attributed to the expanding stage the company is currently in. It is important to note that management is actively seeking different corporate policies to ensure a consistent and viable business model.
Blue Water Biotech Inc

Blue Water Biotech Inc Faces Mounting Outlays as Financial Results Continue to Underwhelm in Q1 2023

As a journalist, I closely examined the financial results of Blue Water Biotech Inc and tried to interpret them to the best of my ability. The company recorded a cumulative net loss of $-14 million during the 12 months ending in the first quarter of 2023, which resulted in a negative return on equity (ROE) of -64.24%. This is certainly not a very encouraging sign for investors.
Furthermore, within the Major Pharmaceutical Preparations industry, 218 other companies had a higher return on equity compared to Blue Water Biotech. This implies that the company is lagging behind its peers in terms of profitability and efficiency. However, there is some positive news as well. The return on equity ranking has improved from 3711 in the fourth quarter of 2022 to 2911 in the current quarter.









Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com